And Faiez Zannad.

We calculated that with a sample of 5400 patients, the analysis would have 91 percent capacity to determine the noninferiority of alogliptin to placebo for the 1.8 and 1.3 margins, with the assumption of a true hazard ratio of justContinue reading… And Faiez Zannad.